News & Updates
Filter by Specialty:
SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality
Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.
SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality
12 Aug 2024
1-year mortality elevated after procedural/spontaneous myocardial infarction
A significantly higher 1-year mortality is seen following procedural myocardial infarction (pMI) and spontaneous MI (spMI) with troponin peak >35x the upper reference level (URL), reports a study. On the other hand, only spMI demonstrates a significant influence on mortality for troponin levels ≤35x.
1-year mortality elevated after procedural/spontaneous myocardial infarction
04 Aug 2024
Asian patients with HFmrEF at high risk of atherosclerotic burden
Among Asian patients with heart failure (HF), those experiencing HF with mildly reduced ejection fraction (HFmrEF) constitute a substantial burden, according to a Singapore study.
Asian patients with HFmrEF at high risk of atherosclerotic burden
03 Aug 2024
CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.
